Inhibikase Therapeutics, Inc. , a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson’s disease and related disorders as well as other diseases arising from protein kinases, today announced the appointment of Ms. Gisele Dion to its Board of Directors, effective September 1, 2022. Ms. Dion will serve as chair of the Audit Committee and a member of the Compensation Committee following the retirement of Ms. Elizabeth O’Farrell from the Company’s Board of Directors, effective immediately.
“I am excited to have Gisele join the Board of Inhibikase. She brings a wealth of public company experience having led financial, accounting and M&A strategies across large pharma,” commented Milton H. Werner, Ph.D., President and Chief Executive Officer. “We look forward to leveraging her expertise, which we believe complements our board, as we seek to improve the lives of patients suffering from devastating neurodegenerative and other Abl-kinase dependent diseases. In addition, on behalf of the entire Board of Directors, I want to thank Liz for her service and contributions to Inhibikase over the last three and a half years.”
Ms. Dion is currently a member of the Board of Directors at Cytek Biosciences and most recently served as an Audit Advisor Group Member for the Pharmaceutical Research and Manufacturers of America (PhRMA). Previously, she served as the Senior Vice-President and Chief Accounting Officer at Takeda Pharmaceuticals where she advised the CFO and protected assets, including $30B+ in revenue. While at Takeda, Ms. Dion successfully led the company through SEC registration and guided change management initiatives. Prior to Takeda, she was the Chief Accounting Officer and Corporate Controller at Shire Pharmaceuticals, where she spearheaded M&A integrations, SEC adherence and GAAP compliance from 2016 to 2019, when it was acquired by Takeda. Earlier, Ms. Dion was Corporate Controller at Biogen. Ms. Dion holds a B.S. in Accounting and Management Information Systems from Fairfield University.
“It is a privilege to join the Inhibikase team as the Company continues to advance its novel therapeutics in the clinic, providing hope for patients with Parkinson’s disease,” remarked Ms. Dion. “I am excited about Inhibikase’s approach that has the potential to alter the course of neurodegenerative diseases, such as Parkinson’s. Moreover, I look forward to bringing my extensive financial and accounting expertise to the table, and look forward to helping guide the Company’s success.”
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company developing therapeutics for Parkinson’s disease and related disorders. Inhibikase’s multi-therapeutic pipeline focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson’s disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. Its multi-therapeutic pipeline is pursuing Parkinson’s-related disorders of the brain and GI tract, orphan indications related to Parkinson’s disease such as Multiple System Atrophy, and drug delivery technologies for kinase inhibitors such as IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate that the Company believes will provide a better patient experience with fewer on-dosing side-effects. The Company’s RAMP™ medicinal chemistry program has identified a number of follow-on compounds to IkT-148009 to be potentially applied to other cognitive and motor function diseases of the brain. Inhibikase is headquartered in Atlanta, Georgia with offices in Boston, Massachusetts.
Milton H. Werner, Ph.D.
President & CEO